Upper GI cancer Highlights from ASCO GI 2023 - Part 1

Upper GI cancer Highlights from ASCO GI 2023 - Part 1

This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023. Dr Nataliya Uboha (University of Wisconsin, USA) and Dr Efrat Dotan(Fox Chase Cancer Center, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.

The experts start by covering a number of metastatic studies. First of all, they discuss SPOTLIGHT, a study which investigated the novel agent zolbetuximab as first line treatment in patients with claudin-18.2+/HER2 locally advanced unresectable or metastatic gastroesophageal cancer. Next they discuss Rationale 305, a study that looked at the activity of tislelizumab in combination with chemotherapy versus chemotherapy alone in patients with PD-L1 positive tumours. They also discussed the three-year follow up results from CheckMate 649, looking at nivolumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced gastroesophageal cancer. The discussion then moves on to INTEGRATE IIa, a study comparing regorafenib with placebo in refractory advanced gastroesophageal cancer.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(90)

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...

12 Mars 23min

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...

17 Dec 202525min

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...

7 Nov 202527min

Exploring the role of targeted radiopharmaceutical treatment in NETs

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...

30 Sep 202521min

Tackling mPDAC: chemotherapy strategies that matter

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...

19 Maj 202521min

Understanding Rare NSCLC Mutations: Insights, access and support

Understanding Rare NSCLC Mutations: Insights, access and support

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...

14 Maj 202520min

The HER2 diagnostic and treatment landscape in NSCLC

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...

28 Apr 202518min

The HER2 Diagnostic and Treatment Landscape in NSCLC

The HER2 Diagnostic and Treatment Landscape in NSCLC

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...

15 Apr 202521min

Populärt inom Utbildning

historiepodden-se
rss-bara-en-till-om-missbruk-medberoende-2
det-skaver
nu-blir-det-historia
harrisons-dramatiska-historia
not-fanny-anymore
roda-vita-rosen
rss-viktmedicinpodden
sektledare
johannes-hansen-podcast
kan-jag-sa-kan-du-podden
i-vantan-pa-katastrofen
allt-du-velat-veta
sa-in-i-sjalen
rikatillsammans-om-privatekonomi-rikedom-i-livet
rss-max-tant-med-max-villman
rss-foraldramotet-bring-lagercrantz
rss-ar-det-rimligt
vi-gar-till-historien
rss-basta-livet